Related Experiment Video
Updated: Feb 18, 2026
09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
18.1K
TMEM106B deficiency exacerbates α-synuclein aggregation in Parkinson's disease
Lanxia Meng1, Congcong Liu1, Meihui Li1
1Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Brain : a Journal of Neurology
|February 17, 2026
Summary
Reduced TMEM106B protein levels worsen Parkinson's disease (PD) by promoting toxic alpha-synuclein aggregation. This deficiency impairs lysosomal function, leading to lipid buildup and hindering protein clearance, ultimately accelerating PD progression.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Parkinson's disease (PD) involves alpha-synuclein aggregation, but its regulation is unclear.
- TMEM106B, a lysosomal protein, is linked to neurodegeneration and brain aging.
Purpose of the Study:
- Investigate the role of TMEM106B in Parkinson's disease pathogenesis.
- Elucidate the molecular mechanisms linking TMEM106B deficiency to alpha-synuclein aggregation and neurotoxicity.
Main Methods:
- Analysis of TMEM106B levels in Parkinson's disease brains.
- TMEM106B knockdown in primary neurons and mouse models.
- Assessment of lysosomal function, lipid metabolism, and alpha-synuclein aggregation.
- Evaluation of cathepsin D activity and alpha-synuclein degradation.
Main Results:
- TMEM106B is reduced in Parkinson's disease brains.
- TMEM106B knockdown exacerbates alpha-synuclein aggregation and neurotoxicity.
- Deficiency impairs lysosomal acidification, alters lipid metabolism, and promotes lipid droplet formation.
- Lipid droplets enhance alpha-synuclein aggregation and seeding activity.
- TMEM106B deficiency reduces cathepsin D activity, inhibiting alpha-synuclein degradation.
Conclusions:
- TMEM106B deficiency is a key factor in Parkinson's disease pathogenesis.
- Reduced TMEM106B accelerates alpha-synuclein aggregation and impairs its clearance via lysosomal dysfunction.
- Targeting TMEM106B or related pathways may offer therapeutic strategies for Parkinson's disease.
Keywords:
Parkinson’s diseaselipid metabolismneurodegenerative diseasestransmembrane protein 106B (TMEM106B)More Related Videos
Related Concept Videos
01:37Neural Regulation
43.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.5K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K